Skip to main content
. 2024 Apr 26;9(5):103008. doi: 10.1016/j.esmoop.2024.103008

Figure 2.

Figure 2

(A) Overall survival (OS) and (B) relative survival (RS) of patients diagnosed with nonmetastatic invasive hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer from the date of diagnosis, according topredefined risk profile. CI, confidence interval.